Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 52

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 52
---
 fiscal year 2023, the CHCC retained an independent compensation consultant, Mercer, to review our peer group of companies and to provide competitive market data on the salary, short-term incentive compensation, and long-term incentive compensation of executive officers at comparable companies within our industry (the "2023 Mercer Executive Compensation Review"). The CHCC used this competitive market data on compensation in determining annual base salaries, short-term (annual) incentive compensation, and long-term equity incentive compensation for our executive officers for fiscal year 2024 . As a basis for the source market data for the 2023 Mercer Executive Compensation Review, Mercer used the compensation data from the group of 19 peer companies set forth in the table below (the " 2024 Peer Group"). Based on input from Mercer, in order to provide for a more comparable peer group, the CHCC modified the Company's peer group by adding Veracyte, Inc., a Company competitor, to the Company's peer group and removed bluebird bio, Inc. We believe that the compensation information obtained from the 2023 Mercer Executive Compensation Review provides us with appropriate compensation data and benchmarks for the 2024 fiscal year compensation decisions because it is derived from companies operating in the diagnostic, pharmaceutical, and biotechnology industries and have similar factors such as number of employees, total assets, market value, revenues, and net income.

| Alkermes plc                    |     | Ironwood Pharmaceuticals, Inc.  |
| BioMarin Pharmaceutical Inc.    |     | Jazz Pharmaceuticals plc        |
| Bio-Techne Corporation          |     | Natera, Inc.                    |
| Coherus BioSciences, Inc.       |     | Neogenomics, Inc.               |
| Exact Sciences Corporation      |     | Neurocrine Biosciences Inc.     |
| Exelixis Inc.                   |     | Seagen Inc.                     |
| lncyte Corporation              |     | United Therapeutics Corporation |
| Intercept Pharmaceuticals, Inc. |     | Vanda Pharmaceuticals Inc.      |
| Invitae Corporation             |     | Veracyte, Inc.                  |
| Ionis Pharmaceuticals, Inc.     |     |                                 |

In addition, Mercer gathered competitive market data from published surveys in the biotech industry for similarly sized entities as reflected in the 2022 Mercer Benchmark - United States Survey, 2022 Mercer SIRS Executive Survey and the 2023 Radford Global Life Sciences Survey. To determine competitive market compensation, where possible, composite survey data were equally blended with